The domain within your query sequence starts at position 57 and ends at position 554; the E-value for the WTX domain shown below is 5.2e-199.
GMVRSRTHDGLAEVLVLEGSKKEEPPGGSDHSGARPIPGPPKPSGPGLGSLASSSVAKSH SFFSLLKKNGRSETGKGDHAEASKAGGKQKRGLKGIFSSMRWHRRDKRGKEEEEKAVRAA GPGNLVLPGSLTASLECVKEEPPRAARRPDSPGQDASRHAAGEPAGGEQAPASAESAPER ICLEAGSPTGSGDQSSRGEDAEGHRREEKPGAALESGAGEVQAAEDASKTGDVPIKTVPL VDSEGGSGRASAVPDPSSVDPPSDPSADRICLMFSDVTSLKSFDSLTGCGDIIADPEEEA GPSCDKHVPGPGKPVLSKKNASVVAYQGGGEEMASPDQVDDTYLPEFWDMLSQTEDQGQG TQEGAAKAATASDIKLAPETSSDTRCGEAAKDMSSVKRRRLHRIPIESQQKEEPKHPEKE HQEGVPNSDEGYWDSTTPGPEEESISNSSSSKKVVIPRDSDSGDALCDLYVEPEASPATL PATEDPPCLSRLKPVSPG
WTX |
![]() |
---|
PFAM accession number: | PF09422 |
---|---|
Interpro abstract (IPR019003): | This entry includes APC membrane recruitment protein 1/2/3 (Amer1/2/3). Amer1, also known as WTX, binds to the tumour suppressor adenomatous polyposis coli and acts as an inhibitor of Wnt signaling by inducing beta-catenin degradation [ (PUBMED:21498506) ]. Amer2 is a negative regulator of Wnt/beta-catenin signaling involved in neuroectodermal patterning [ (PUBMED:22128170) ]. WTX is a novel gene mutated in a proportion of Wilms' tumors and in patients suffering from sclerosing bone dysplasia [ (PUBMED:20843316) ]. |
This is a PFAM domain. For full annotation and more information, please see the PFAM entry WTX